Bard reports growth in second quarter of 2012

Bard has announced its financial results for the second quarter of 2012, during which it generated a three-month sales total of $742.6 million (472.86 million pounds).

This represented a two percent year-on-year increase, or four percent when excluding the impact of foreign exchange, with growth coming despite the challenging economic conditions in the US and Europe.

Timothy Ring, chairman and chief executive officer of Bard, said the firm is sticking to its historic strategy of long-term planning coupled with an appropriate level of attention to short-term issues.

He stated that the provision of clinically effective products at a value that benefits the entire healthcare system will be essential to success in the medical technology sector in future.

Mr Ring added: "Our teams are well positioned to identify unmet needs and provide successful solutions for our customers, and we see significant long-term opportunity as we continue to execute on our strategy."

This week, the company also announced the launch of a new clinical trial comparing its Lutonix Drug Coated PTA Dilatation Catheter to a standard angioplasty balloon for the treatment of peripheral arterial disease.